Ad
related to: mrns
Search results
Marinus Pharmaceuticals (NASDAQ:MRNS) Given “Neutral” Rating at Robert W. Baird
ETF DAILY NEWS· 16 hours agoMarinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at Robert W. Baird in a research note issued ...
Marinus Pharmaceuticals Inc [MRNS] CHIEF COMMERCIAL OFFICER makes an insider purchase of 2,153...
Knox Daily· 13 hours agoAs published in a research note from Robert W. Baird on April 16, 2024, Marinus Pharmaceuticals Inc [MRNS] has been rated down from an Outperform to a Neutral and the price ...
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
InvestorPlace· 3 days agoMarinus Pharmaceuticals (NASDAQ:MRNS) stock is taking a beating on Monday after the pharmaceutical...
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Zacks via Yahoo Finance· 2 days agoInterim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the...
Marinus stock target cut on reduced ganaxolone estimates By Investing.com
Investing.com· 1 day agoOn Wednesday, Truist Securities adjusted its outlook on Marinus (NASDAQ:MRNS) Pharmaceuticals...
...Neumora Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Marinus...
Benzinga· 3 days agoU.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss -...
Benzinga· 2 days agoMarinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus...
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $21.21 Average Price Target from Analysts
ETF DAILY NEWS· 6 days agoMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat ...
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints
Seeking Alpha· 3 days agoMarinus Pharmaceuticals stock plunges 78% as interim analysis for ganaxolone fails to meet criteria. Read more here.
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March - Longeveron (NASDAQ:LGVN), Marinus...
Benzinga· 3 days agoU.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday....
